Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Colorectal Cancer – Pipeline Review, H2 2016, provides an overview of the Metastatic Colorectal Cancer (Oncology) pipeline landscape.
Metastatic colorectal cancer is a cancer that spread to other parts of the body. When colon or rectal cancer spreads, it most often spreads to the liver. Sometimes it spreads to the lungs, bones, or other organs in the body. The most common symptoms are belly pain, especially gas pains, cramps, or a feeling of fullness, blood in stool or very dark stools. Treatment of metastatic colorectal cancer includes options such as chemotherapy, surgery, biological therapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Colorectal Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metastatic Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 59, 34, 4, 15, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 4 molecules, respectively.Metastatic Colorectal Cancer.
Metastatic Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc
AB Science SA
AbbVie Inc
Advenchen Laboratories LLC
Alchemia Ltd
Apexigen Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bavarian Nordic A/S
Bayer AG
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Celgene Corp
Celltrion Inc
Cipla Ltd
Coherus BioSciences Inc
Cornerstone Pharmaceuticals Inc
DanDrit Biotech A/S
Dr. Reddy's Laboratories Ltd
EirGenix Inc.
Eisai Co Ltd
Eli Lilly and Company
EnGeneIC Ltd
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Genor BioPharma Co Ltd
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glycotope GmbH
Hemispherx Biopharma Inc
Hutchison MediPharma Ltd
Ignyta Inc
Immodulon Therapeutics Ltd
Immunomedics Inc
Immunovative Therapies Ltd
Karyopharm Therapeutics Inc
Mabion SA
Mabtech Limited
mAbxience SA
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
MolMed SpA
Mologen AG
Morphotek Inc
Mycenax Biotech Inc
Natco Pharma Ltd
Nektar Therapeutics
Nippon Kayaku Co Ltd
Northwest Biotherapeutics Inc
Novartis AG
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Pivot Pharmaceuticals Inc
Precision Biologics Inc
PsiOxus Therapeutics Ltd
R Pharm
Regeneron Pharmaceuticals Inc
Richter Gedeon Nyrt
Shanghai Henlius Biotech Co., Ltd.
Shire Plc
Sillajen Biotherapeutics
Symphogen A/S
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Tocagen Inc
Vaximm AG
XBiotech Inc
'
Table of Contents
Table of Contents 2
Introduction 7
Metastatic Colorectal Cancer Overview 8
Therapeutics Development 9
Metastatic Colorectal Cancer - Therapeutics under Development by Companies 11
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 18
Metastatic Colorectal Cancer - Pipeline Products Glance 19
Metastatic Colorectal Cancer - Products under Development by Companies 23
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 32
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 33
Metastatic Colorectal Cancer - Therapeutics Assessment 122
Drug Profiles 149
Metastatic Colorectal Cancer - Dormant Projects 682
Metastatic Colorectal Cancer - Discontinued Products 692
Metastatic Colorectal Cancer - Product Development Milestones 695
Appendix 710
List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H2 2016 25
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2016 26
Number of Products under Development by Companies, H2 2016 27
Number of Products under Development by Companies, H2 2016 (Contd..1) 28
Number of Products under Development by Companies, H2 2016 (Contd..2) 29
Number of Products under Development by Companies, H2 2016 (Contd..3) 30
Number of Products under Development by Companies, H2 2016 (Contd..4) 31
Number of Products under Development by Companies, H2 2016 (Contd..5) 32
Number of Products under Development by Companies, H2 2016 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Comparative Analysis by Late Stage Development, H2 2016 35
Comparative Analysis by Clinical Stage Development, H2 2016 36
Comparative Analysis by Early Stage Development, H2 2016 37
Comparative Analysis by Unknown Stage Development, H2 2016 38
Products under Development by Companies, H2 2016 39
Products under Development by Companies, H2 2016 (Contd..1) 40
Products under Development by Companies, H2 2016 (Contd..2) 41
Products under Development by Companies, H2 2016 (Contd..3) 42
Products under Development by Companies, H2 2016 (Contd..4) 43
Products under Development by Companies, H2 2016 (Contd..5) 44
Products under Development by Companies, H2 2016 (Contd..6) 45
Products under Development by Companies, H2 2016 (Contd..7) 46
Products under Development by Companies, H2 2016 (Contd..8) 47
Products under Investigation by Universities/Institutes, H2 2016 48
Metastatic Colorectal Cancer - Pipeline by 3SBio Inc, H2 2016 49
Metastatic Colorectal Cancer - Pipeline by AB Science SA, H2 2016 50
Metastatic Colorectal Cancer - Pipeline by AbbVie Inc, H2 2016 51
Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 52
Metastatic Colorectal Cancer - Pipeline by Alchemia Ltd, H2 2016 53
Metastatic Colorectal Cancer - Pipeline by Apexigen Inc, H2 2016 54
Metastatic Colorectal Cancer - Pipeline by ArQule Inc, H2 2016 55
Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2016 56
Metastatic Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2016 57
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 58
Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2016 59
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 60
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H2 2016 61
Metastatic Colorectal Cancer - Pipeline by Biocon Ltd, H2 2016 62
Metastatic Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2016 63
Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H2 2016 64
Metastatic Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016 65
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 66
Metastatic Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2016 67
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 68
Metastatic Colorectal Cancer - Pipeline by Burzynski Research Institute Inc, H2 2016 69
Metastatic Colorectal Cancer - Pipeline by Celgene Corp, H2 2016 70
Metastatic Colorectal Cancer - Pipeline by Celltrion Inc, H2 2016 71
Metastatic Colorectal Cancer - Pipeline by Cipla Ltd, H2 2016 72
Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 73
Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 74
Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H2 2016 75
Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 76
Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H2 2016 77
Metastatic Colorectal Cancer - Pipeline by Eisai Co Ltd, H2 2016 78
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2016 79
Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H2 2016 80
Metastatic Colorectal Cancer - Pipeline by Etubics Corp, H2 2016 81
Metastatic Colorectal Cancer - Pipeline by Exelixis Inc, H2 2016 82
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 83
Metastatic Colorectal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 84
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 85
Metastatic Colorectal Cancer - Pipeline by Genzyme Corp, H2 2016 86
Metastatic Colorectal Cancer - Pipeline by Gilead Sciences Inc, H2 2016 87
Metastatic Colorectal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 88
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2016 89
Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016 90
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 91
Metastatic Colorectal Cancer - Pipeline by Ignyta Inc, H2 2016 92
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd, H2 2016 93
Metastatic Colorectal Cancer - Pipeline by Immunomedics Inc, H2 2016 94
Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016 95
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 96
Metastatic Colorectal Cancer - Pipeline by Mabion SA, H2 2016 97
Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H2 2016 98
Metastatic Colorectal Cancer - Pipeline by mAbxience SA, H2 2016 99
Metastatic Colorectal Cancer - Pipeline by MacroGenics Inc, H2 2016 100
Metastatic Colorectal Cancer - Pipeline by MedImmune LLC, H2 2016 101
Metastatic Colorectal Cancer - Pipeline by Merck & Co Inc, H2 2016 102
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H2 2016 103
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 104
Metastatic Colorectal Cancer - Pipeline by Merus NV, H2 2016 105
Metastatic Colorectal Cancer - Pipeline by MolMed SpA, H2 2016 106
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H2 2016 107
Metastatic Colorectal Cancer - Pipeline by Morphotek Inc, H2 2016 108
Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 109
Metastatic Colorectal Cancer - Pipeline by Natco Pharma Ltd, H2 2016 110
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H2 2016 111
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 112
Metastatic Colorectal Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 113
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H2 2016 114
Metastatic Colorectal Cancer - Pipeline by OBI Pharma Inc, H2 2016 115
Metastatic Colorectal Cancer - Pipeline by Oncobiologics Inc, H2 2016 116
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 117
Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 118
Metastatic Colorectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 119
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc, H2 2016 120
Metastatic Colorectal Cancer - Pipeline by Pharma Mar SA, H2 2016 121
Metastatic Colorectal Cancer - Pipeline by Pivot Pharmaceuticals Inc, H2 2016 122
Metastatic Colorectal Cancer - Pipeline by Precision Biologics Inc, H2 2016 123
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2016 124
Metastatic Colorectal Cancer - Pipeline by R Pharm, H2 2016 125
Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 126
Metastatic Colorectal Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 127
Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 128
Metastatic Colorectal Cancer - Pipeline by Shire Plc, H2 2016 129
Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016 130
Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H2 2016 131
Metastatic Colorectal Cancer - Pipeline by Synermore Biologics Co Ltd, H2 2016 132
Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 133
Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016 134
Metastatic Colorectal Cancer - Pipeline by Tocagen Inc, H2 2016 135
Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H2 2016 136
Metastatic Colorectal Cancer - Pipeline by XBiotech Inc, H2 2016 137
Assessment by Monotherapy Products, H2 2016 138
Assessment by Combination Products, H2 2016 139
Number of Products by Stage and Target, H2 2016 141
Number of Products by Stage and Mechanism of Action, H2 2016 151
Number of Products by Stage and Route of Administration, H2 2016 162
Number of Products by Stage and Molecule Type, H2 2016 164
Metastatic Colorectal Cancer - Dormant Projects, H2 2016 698
Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H2 2016 699
Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H2 2016 700
Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H2 2016 701
Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H2 2016 702
Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H2 2016 703
Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H2 2016 704
Metastatic Colorectal Cancer - Dormant Projects (Contd..7), H2 2016 705
Metastatic Colorectal Cancer - Dormant Projects (Contd..8), H2 2016 706
Metastatic Colorectal Cancer - Dormant Projects (Contd..9), H2 2016 707
Metastatic Colorectal Cancer - Discontinued Products, H2 2016 708
Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H2 2016 709
Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H2 2016 710
List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H2 2016 25
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2016 26
Number of Products under Development by Companies, H2 2016 27
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Comparative Analysis by Late Stage Development, H2 2016 35
Comparative Analysis by Clinical Stage Development, H2 2016 36
Comparative Analysis by Early Stage Products, H2 2016 37
Assessment by Monotherapy Products, H2 2016 138
Assessment by Combination Products, H2 2016 139
Number of Products by Top 10 Targets, H2 2016 140
Number of Products by Stage and Top 10 Targets, H2 2016 140
Number of Products by Top 10 Mechanism of Actions, H2 2016 150
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 150
Number of Products by Top 10 Routes of Administration, H2 2016 161
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161
Number of Products by Top 10 Molecule Types, H2 2016 163
Number of Products by Stage and Top 10 Molecule Types, H2 2016 163
